Amgen Acquires Dark Blue Therapeutics

Amgen Completes Acquisition of Horizon Therapeutics plc

October 6, 2023

Biotechnology

Amgen completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, valuing the transaction equity at approximately $27.8 billion. The deal expands Amgen’s inflammation and rare-disease portfolio by adding Horizon’s first-in-class, early-in-lifecycle medicines such as TEPEZZA, KRYSTEXXA, and UPLIZNA.

Pfizer Acquires Global Blood Therapeutics (GBT) for $5.4 Billion

August 8, 2022

Biotechnology

Pfizer entered into a definitive agreement to acquire Global Blood Therapeutics (GBT), paying $68.50 per share in cash for an enterprise value of about $5.4 billion. The deal adds GBT’s sickle cell disease portfolio, including Oxbryta (voxelotor), along with clinical pipeline assets such as GBT021601 (GBT601) and inclacumab.

Biotage AB Acquires ATDBio

October 20, 2021

Biotechnology

Swedish life sciences company Biotage AB has acquired UK-based oligonucleotide specialist ATDBio for approximately £45 million in cash and shares. The deal brings ATDBio’s complex DNA/RNA synthesis capabilities and its founders into the Biotage Group to accelerate capability expansion and scale molecular diagnostics, therapeutics and sequencing support services.

Amgen Acquires Teneobio for $900M with Up to $1.6B in Milestones

July 27, 2021

Biotechnology

Amgen agreed to acquire clinical-stage biotechnology company Teneobio for $900 million in upfront cash plus potential contingent milestone payments up to $1.6 billion. The acquisition adds Teneobio's heavy-chain antibody discovery platform, bispecific/multispecific antibody technologies and a Phase 1 T-cell engager (TNB-585), strengthening Amgen's antibody research capabilities and oncology pipeline.

Amgen Inc. Acquires Rodeo Therapeutics

March 30, 2021

Biotechnology

Amgen Inc. has agreed to acquire privately held Rodeo Therapeutics, a Seattle-based biopharmaceutical company focused on small-molecule modulators of prostaglandin biology, including a lead 15-PGDH program. The deal includes a $55 million upfront cash payment plus up to $666 million in potential contingent milestone payments and is intended to expand Amgen's inflammation and tissue-regeneration capabilities.

BioNTech Acquires Neon Therapeutics

January 16, 2020

Biotechnology

BioNTech SE will acquire Neon Therapeutics, Inc. in an all-stock transaction valued at approximately $67.0 million. Neon, a Cambridge-based developer of neoantigen-targeted T cell therapies, will become a wholly owned subsidiary of BioNTech to expand BioNTech’s T cell therapy capabilities and U.S. presence.